The stock of Atreca, Inc. (NASDAQ:BCEL) is a huge mover today! The stock decreased 2.77% or $0.37 during the last trading session, reaching $12.97. About 220,749 shares traded or 111.89% up from the average. Atreca, Inc. (NASDAQ:BCEL) has 0.00% since December 4, 2018 and is . It has by 0.00% the S&P500.
The move comes after 5 months negative chart setup for the $362.65M company. It was reported on Dec, 4 by Barchart.com. We have $12.58 PT which if reached, will make NASDAQ:BCEL worth $10.88 million less.
Analysts await Atreca, Inc. (NASDAQ:BCEL) to report earnings on February, 11. After $-0.57 actual EPS reported by Atreca, Inc. for the previous quarter, Wall Street now forecasts 17.54 % negative EPS growth.
More notable recent Atreca, Inc. (NASDAQ:BCEL) news were published by: Benzinga.com which released: “Stocks That Hit 52-Week Lows On Wednesday – Benzinga” on November 27, 2019, also Seekingalpha.com with their article: “Atreca Proposes Terms For $125 Million IPO – Seeking Alpha” published on June 14, 2019, Seekingalpha.com published: “UniQure and ViewRay among healthcare gainers; Cara Therapeutics among losers – Seeking Alpha” on December 03, 2019. More interesting news about Atreca, Inc. (NASDAQ:BCEL) were released by: Globenewswire.com and their article: “Atreca Announces Pricing of Initial Public Offering – GlobeNewswire” published on June 19, 2019 as well as Seekingalpha.com‘s news article titled: “Healthcare – Top 5 Gainers / Losers – Seeking Alpha” with publication date: December 04, 2019.
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody immunotherapeutics to treat a range of solid tumor types. The company has market cap of $362.65 million. The Company’s lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. It currently has negative earnings. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.